Cypherpunk Technologies Inc. earnings releases CYPH

Cypherpunk Technologies Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of $0.18. It usually reports 43–75 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–75 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 12, 2026
43 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
39
+336.7%
0.18
+145.0%
May 14, 2026
44 days after quarter end
Q1 FY2026
ended Mar 31, 2026
—
-77
-399.9%
-0.46
-24.3%
Mar 16, 2026
75 days after quarter end
Q4 FY2025
ended Dec 31, 2025
—
40
+360.5%
0.26
+168.3%
Nov 12, 2025
43 days after quarter end
Q3 FY2025
ended Sep 30, 2025
—
-3
+81.8%
-0.08
+81.8%
Aug 14, 2025
45 days after quarter end
Q2 FY2025
ended Jun 30, 2025
—
-17
+17.3%
-0.40
+23.1%
May 13, 2025
43 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-15
-11.7%
-0.37
+27.5%
Nov 13, 2024
44 days after quarter end
Q3 FY2024
ended Sep 30, 2024
—
-18
-32.7%
-0.44
+13.7%
Aug 12, 2024
43 days after quarter end
—
ended Jun 30, 2024
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CYPH (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1509745
Former names
LEAP THERAPEUTICS, INC. (until Nov 12, 2025); Dekkun Corp (until Jan 7, 2011)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.